“Americans deserve fair prices when public funding provides tremendous financial benefit for drug manufacturers. For far too long, drug companies have exploited taxpayer-funded foundational research, enriching themselves as they price-gouge Americans for newly developed medications. The decision to exercise march-in rights represents an important step for fairer drug prices. For the first time, price can be a factor in determining public accessibility of taxpayer-funded drugs. Without public funding, many new medicines would never make it to market. At the very least, taxpayers should receive a return on their investment through fairer prices. We are confident lower drug prices will increase medication access, leading to better health outcomes. AHF welcomes policies that help make prescription drugs more affordable for all Americans,” said Tom Myers, AHF General Counsel and Chief of Public Affairs.
###
